Science Corporation launches retinal implant for macular degeneration in Europe

Science Corporation has initiated the European commercial rollout of its retinal implant designed to treat age-related macular degeneration. The company is currently targeting a U.S. market entry by 2027, pending regulatory milestones. The clinical efficacy and long-term safety profile of the device remain the primary variables for broader adoption.